Necrotizing Enterocolitis Market: Steep Growth Ahead as Pipeline Advances Toward First Approved Therapy by 2036

DelveInsight's "Necrotizing Enterocolitis Market Insights, Epidemiology, and Market Forecast-2036" report offers an in-depth understanding of Necrotizing Enterocolitis (NEC), historical and forecasted epidemiology, as well as market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

To know more about the Necrotizing Enterocolitis market outlook, drug uptake, treatment scenario, and epidemiology trends, visit: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Key Highlights from the Necrotizing Enterocolitis Market Report
• The Necrotizing Enterocolitis market size was valued at approximately USD 30 million across the 7MM in 2025 and is expected to reach nearly USD 800 million by 2036, growing at a CAGR of approximately 26% during 2026-2036.
• In March 2026, Noveome Biotherapeutics announced that the independent Data Safety Monitoring Board (DSMB) completed its review of safety data from Cohort 1 of the ongoing ST266 clinical trial in neonates with NEC.
• In March 2026, Infant Bacterial Therapeutics reported that pivotal Phase III "Connection Study" results for IBP-9414 were published in Pediatric Research, a Nature publication.
• As of December 2025, Infant Bacterial Therapeutics partnered with BioConnection for manufacturing of IBP-9414, and in November 2025 announced plans to pursue an accelerated approval pathway.
• There are currently no approved pharmaceutical therapies specifically indicated for NEC, highlighting a significant unmet medical need.
• The United States continues to report the highest number of very low birth weight (≤1,500 g) preterm infants, with approximately 3,000-5,000 NEC cases annually.
• Germany records the highest number of VLBW preterm infants within the EU4, followed by France.
• Japan reports relatively low incidence rates, with approximately 100-200 NEC cases annually.
• Infant Bacterial Therapeutics remains the only company with a registration-enabling Phase III candidate, while several other companies maintain early-stage programs.
• Key companies include Infant Bacterial Therapeutics, Leadiant Biosciences, Siolta Therapeutics, Noveome Biotherapeutics, and Plakous Therapeutics.
• Key therapies include IBP-9414, STP206, STMC-106, ST266, and Protego-PD.
• The market is expected to transform as microbiome-based and preventive therapies advance through development, with IBP-9414 emerging as a potential first-in-class therapy.

Necrotizing Enterocolitis Overview
Necrotizing Enterocolitis (NEC) is a severe and potentially fatal gastrointestinal emergency that primarily affects premature infants in neonatal intensive care units (NICUs). The disease is characterized by intestinal inflammation, bacterial invasion, and progressive tissue necrosis that can lead to perforation, sepsis, and death.
Although the exact cause remains unclear, intestinal immaturity, abnormal bacterial colonization, and excessive inflammatory responses are considered major contributing factors. Common symptoms include:
• Poor feeding
• Vomiting
• Lethargy
• Abdominal distension
• Abdominal tenderness
Diagnosis typically involves clinical evaluation supported by laboratory testing and imaging studies. Treatment depends on disease severity, ranging from bowel rest and antibiotics in early stages to surgical intervention in advanced cases.

Get a free sample of the Necrotizing Enterocolitis Market Report: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Necrotizing Enterocolitis Epidemiology Insights
The epidemiology section provides insights into historical and forecasted patient populations across the 7MM. It analyzes disease trends, prevalence patterns, and factors influencing future disease burden.

According to DelveInsight's analysis:
The incidence of NEC in high-income regions, including the United States, EU4, and the United Kingdom, has stabilized or modestly declined due to advances in neonatal care, standardized NICU practices, improved infection control, and increased use of human milk feeding strategies.
Across the 7MM, the population of preterm infants weighing ≤1,500 g is expected to remain stable or increase slightly through 2030, primarily because of improved neonatal survival rates.

Epidemiology Segmentation
The report evaluates:
• Total Incident Cases of Preterm Infants by Birth Weight (≤1,500 g)
• Total Incident Cases of Necrotizing Enterocolitis

Download the report to explore NEC epidemiology trends: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Necrotizing Enterocolitis Therapies and Key Companies
• IBP-9414 - Infant Bacterial Therapeutics
• STMC-106 - Siolta Therapeutics
• ST266 - Noveome Biotherapeutics
• Protego-PD - Plakous Therapeutics
• STP206 - Leadiant Biosciences

Emerging Necrotizing Enterocolitis Drugs Uptake
The report evaluates anticipated adoption trends for emerging therapies between 2026 and 2036.

IBP-9414
IBP-9414, containing Lactobacillus reuteri, is currently being evaluated in a registration-enabling Phase III study. The therapy aims to become the world's first approved probiotic drug for the prevention of NEC and sepsis in premature infants, with regulatory submissions anticipated in 2026.

Market Adoption Outlook
• IBP-9414 is expected to demonstrate moderate-to-strong uptake following approval.
• STP206 is anticipated to experience gradual adoption as additional clinical evidence becomes available.
• Preventive strategies remain a major area of focus due to the absence of targeted approved therapies.

Current prevention approaches include:
• Early feeding with colostrum and mother's milk
• Nutritional optimization
• Probiotic supplementation
• Environmental management
• Skin-to-skin care

Discover therapies expected to capture significant market share: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Necrotizing Enterocolitis Market Forecast
Currently, NEC management relies on supportive care measures, including:
• Bowel rest
• Broad-spectrum antibiotics
• Parenteral nutrition
• Surgical intervention in severe cases

Key market growth drivers include:
• Rising survival rates among extremely premature infants
• Significant unmet medical needs
• Increasing focus on preventive treatment strategies
• Advancements in microbiome-based therapeutics
• Progress of late-stage candidates such as IBP-9414 toward commercialization
As novel therapies move closer to regulatory approval, the NEC market is expected to experience substantial growth through 2036.

Scope of the Necrotizing Enterocolitis Market Report
• Study Period: 2022-2036
• Coverage: 7MM (United States, EU4, United Kingdom, and Japan)
• Key Companies: Infant Bacterial Therapeutics, Leadiant Biosciences, Siolta Therapeutics, Noveome Biotherapeutics, Plakous Therapeutics, and others
• Key Therapies: IBP-9414, STP206, STMC-106, ST266, Protego-PD, and others
• Therapeutic Assessment: Current and emerging therapies
• Market Dynamics: Drivers and barriers
• Competitive Intelligence: SWOT Analysis, PESTLE Analysis, Porter's Five Forces, Conjoint Analysis, and Market Entry Strategies
• Additional Insights: Unmet needs, KOL perspectives, analyst views, market access, and reimbursement analysis

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432, Las Vegas, NV, United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading healthcare business consulting and market research firm focused exclusively on the life sciences sector. The company supports pharmaceutical, biotechnology, and medical device organizations with comprehensive market intelligence, competitive assessments, forecasting, and strategic consulting services designed to accelerate business growth and improve decision-making.

This release was published on openPR.